Positive Tone in today's NRI like the tone of the Phase 2b trial mentioned in the Q3 results (emphasis added):
"During the third quarter we were very pleased to report impressive results from our open-label Phase 2 study of PRX302 for the treatment of moderate to severe benign prostatic hyperplasia, and to announce completion of enrollment in our Phase 2b TRIUMPH trial of PRX302," said Dr. Fahar Merchant, President and CEO of Protox. "In our open label study, patients who received an optimal dose of PRX302 demonstrated a twelve point improvement in the International Prostate Symptom Score (IPSS) after one year following a single treatment, almost double that seen with oral therapies and comparable to many surgical procedures. These very encouraging data have only increased our anticipation for the top-line results from our TRIUMPH study, which are expected within the next 2 months."
So it looks like the results will be before Christmas or right afterwards, depending on the complexity of the analysis and whatever additional announcements that management may want to accompany the 2b results announcement.
New investors need to get on the train now.
Cheers to the longs, jb